RA n=250 (52.5%) | AS n=119 (24.9%) | PsA n=109 (22.8%) | P-value* | |
Age (years); mean±SD | 53.8±13.9 | 42.6±12.2 | 47.6±12.1 | <0.001 |
Sex; n (%) | ||||
Female | 173 (69.2) | 25 (21.0) | 58 (53.2) | <0.001 |
Male | 77 (30.8) | 94 (79.0) | 51 (46.8) | |
Length of disease evolution in years; Mean±SD | 8.6±7.8 | 7.6±8.2 | 8.0±8.1 | 0.057 |
ESR (mm/h); Median (IR) | n=235 28 (2–140) | n=112 13 (1–140) | n=100 19 (1–101) | <0.001 |
CRP (mg/l); Median (IR) normal range=0–8 | n=232 9 (0–114) | n=116 7 (0–120) | n=96 5 (0–143) | 0.039 |
Haemoglobin (mg/dl); Median ±SD | n=243 13.1±1.5 | n=115 14.2±1.5 | n=103 13.2±1.6 | <0.001 |
Concomitant MTX; n (%) | n=247 126 (51.0) | n=76 6 (7.9) | n=109 54 (49.5) | <0.001 |
Concomitant leflunomide; n (%) | n=237 32 (13.5) | n=116 1 (0.9) | n=108 8 (7.4) | <0.001 |
Daily GC dose (mg); mean±SD† | n=242 7.4±5.7 | n=117 1.4±3.6 | n=104 4.6±5.1 | <0.001 |
Biological therapy; n (%) | Not applicable‡ | |||
Adalimumab | 82 (32.8) | 58 (48.7) | 56 (51.4) | |
Etanercept | 65 (26.0) | 43 (36.1) | 29 (26.6) | |
Abatacept | 34 (13.6) | 0 (0.0) | 0 (0.0) | |
Tocilizumab | 28 (11.2) | 0 (0.0) | 3 (2.8) | |
Infliximab | 7 (2.8) | 1 (0.8) | 4 (3.7) | |
Golimumab | 15 (6.0) | 13 (10.9) | 11 (10.1) | |
Certolizumab | 19 (7.6) | 4 (3.4) | 3 (2.8) | |
Ustekinumab | 0 (0.0) | 0 (0.0) | 3 (2.8) | |
First BT lines; n (%) | 131 (52.4) | 77 (64.7) | 68 (62.4) | 0.040 |
*A value of P< 0.05 was considered to be statistically relevant.
†All glucocorticoids doses were converted to equivalent prednisone dose.
‡Test could not be made because there are some values under 5.
AS, ankylosing spondylitis; BT, biological therapy; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GC, glucocorticoid; IR, interquartile range; n, number of biological therapy lines; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SD, standard deviation.